Whole communities in Africa could be protected from pneumococcus by immunising young children

October 18, 2011

Whole communities in Africa could be protected from pneumococcus by immunising young children

A study led by the Medical Research Council in The Gambia in collaboration with the London School of Hygiene & Tropical Medicine and published in this week's PLoS Medicine shows for the first time in Africa, that vaccinating young children against the pneumococcus (a bacterium that can cause fatal infections) causes a herd effect in which the entire community is protected against this infection.

In a randomised, controlled trial involving 21 villages in rural Gambia, the authors showed that vaccination of young children reduced carriage of vaccine serotype pneumococci (the type of pneumoccus contained in the vaccine) not only in the vaccinated children but also in vaccinated and non-vaccinated older children and adults. Furthermore, the study showed that vaccinating whole communities did not result in a community wide increase in carriage of nonvaccine serotype pneumococci (other types of pneumococci that are not included in the vaccine) in the two-year period after vaccination.

As an alternative method to long-term observational studies and to anticipate the potential long term effects of the introduction of pneumococcal conjugate vaccination in sub-Saharan Africa, the authors conducted a village-randomized trial in The Gambia in which the whole population of some villages were immunized with pneumococcal conjugate vaccine (PCV-7) (vaccinated villages) and in other villages only children <30 months of age at vaccination or other children born during the trial received PCV-7 while older residents received a control vaccine (control villages).

Before immunization, the overall prevalence of pneumococcal carriage in both groups was high at 71.1% and decreased with age. The overall prevalence of pneumococcal carriage at 6, 12, and 22 months after vaccination was similar between vaccinated and control villages, showing a marked fall. However, the prevalence of carriage of vaccine serotype pneumococci was significantly lower in vaccinated than in control villages in all surveys for all age groups. The authors also found that the overall prevalence of pneumococcal carriage fell markedly after vaccination and reached minimum levels at 12 months after vaccination in both study arms and in all age groups.

The authors, led by Anna Roca from the MRC in The Gambia, say: "We have shown here, to our knowledge for the first time in Africa, a herd effect on carriage of [vaccine serotype] pneumococci, which might be translated into herd protection against [invasive pneumococcal disease] in adults, following routine immunization of infants and young children."

They conclude: "Our findings are relevant for other countries in Africa contemplating the introduction of [pneumococcal conjugated vaccines] where the pattern of pneumococcal infection is similar to that in The Gambia."
-end-
Funding: The study was funded by the United Kingdom Medical Research Council. Study vaccines were donated by Wyeth Lederle Vaccines (Pfizer) and they played no role in the design of the study, writing or decision to publish this manuscript.

Competing Interests: All authors declare no conflicts of interest.

Citation: Roca A, Hill PC, Townend J, Egere U, Antonio M, et al. (2011) Effects of Community-Wide Vaccination with PCV-7 on Pneumococcal Nasopharyngeal Carriage in The Gambia: A Cluster-Randomized Trial. PLoS Med 8(10): e1001107. doi:10.1371/journal.pmed.1001107

CONTACT:

Anna Roca
Medical Research Council Laboratories
Atlantic Road
Fajara,
Gambia
2207402746
aroca@mrc.gm

PLOS

Related Vaccine Articles from Brightsurf:

Who should get the COVID-19 vaccine first?
Nineteen global health experts from around the world have proposed a new, three-phase plan for vaccine distribution -- called the Fair Priority Model -- which aims to reduce premature deaths and other irreversible health consequences from COVID-19.

Breakthrough with cancer vaccine
Scientists have developed a new cancer vaccine with the potential to activate the body's immune system to fight a range of cancers, including leukaemia, breast cancer, lung cancer and pancreatic cancers.

How to improve the pneumococcus vaccine
Pneumococcus kills 1 million children annually according to the World Health Organization.

US inroads to better Ebola vaccine
As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.

Successful MERS vaccine in mice may hold promise for COVID-19 vaccine
In a new study, published April 7 in mBio, researchers from the University of Iowa and the University of Georgia demonstrate that a new vaccine fully protects mice against a lethal dose of MERS, a close cousin of COVID-19.

Coronavirus Vaccine: Where are we and what's next? (video)
You might have heard that COVID-19 vaccine trials are underway in Seattle.

Why isn't there a vaccine for staph?
A study from Washington University School of Medicine in St.

Exposing vaccine hesitant to real-life pain of diseases makes them more pro-vaccine
New research from Brigham Young University professors finds there is a better way to help increase support for vaccinations: Expose people to the pain and suffering caused by vaccine-preventable diseases instead of trying to combat people with vaccine facts.

Lifetime flu vaccine?
Another year, another flu vaccine because so far scientists haven't managed to make a vaccine that protects against all strains of flu.

On the horizon: An acne vaccine
A new study published in the Journal of Investigative Dermatology reports important steps that have been taken towards the development of an acne vaccine.

Read More: Vaccine News and Vaccine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.